DolPHIN2

Search

  • About DolPHIN 2
  • Research
    • Clinical trial
    • Qualitative research
    • Health Economics
    • Community Voices
  • Resources
  • News & Events
    • News
    • Events
    • Past events

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

image source: pexels

The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy

The team at the Infectious Diseases Institute, Kampala

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

0

How we work

About DolPHIN 2

Read about the challenges that the DolPHIN 2 project seeks to address and why.

The DolPHIN 2 Consortium

Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.

Community Voices

Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.

1

Resources

11 Aug 2022

Empower, Engage, Educate - Breastfeeding

Video
11 Aug 2022

Empower, Engage, Educate - Delivery

Video
11 Aug 2022

Empower, Engage, Educate - Male Involvement

Video
11 Aug 2022

Empower, Engage, Educate - Mumbwa

Video
View all Resources
1

News

The Ugandan Team Celebrates World Breastfeeding Week

08 Aug 2019

DolPHIN-2 presents primary outcome analysis at CROI 2019

05 Mar 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

20 Jun 2018
View all News and Events

@UoLDolPHIN2 on Twitter

DolPHIN2 investigator @CatrionaWaitt paper was mentioned at #ChivaConference during the #breastfeeding session. Check out the paper here https://t.co/o0H1kwQiDQ
1 week 2 days ago
RT @UNITAID: On #InternationalWomensDay, 8 March, Unitaid remains committed to addressing barriers to improve the lives and health of women in resource-constrained settings. Discover how Unitaid is bridging the gender divide through access to life-saving innovations: https://t.co/o2mhyMNqbo https://t.co/HiqKLimxNK
2 weeks 4 days ago
Laura Else from @LivUniISMIB will be presenting a poster at #CROI2023 today at 14 30 entitled Plasma & urine PK of #dolutegravir and #tenofovir to aid point-of-care testing. Stop by poster 527 to find out more
1 month 2 days ago
RT @covidDDIs: #CROI2023 Stop by poster 515 TODAY at 2h30 pm for a live discussion to learn more about the global collaboration to provide drug interaction guidance for nirmatrelvir/ritonavir @AlicePharmd @FionaMarra @alisonboyle_1 @geschena @KimScarsi
1 month 2 days ago
RT @AdellineTwimu: We successfully disseminated research findings to study participants. Thank you #DolPHIN2 team for making this happen! https://t.co/7FJrsOUl5M
1 month 2 days ago
RT @CatrionaWaitt: The @UoLDolphin2 participant feedback event reminded us all of the power of research to transform lives. Many emotional testimonials from participants of how involvement in the trial brought hope and healing. @UNITAID @TRIO_ARToptim @livuniHLS @IDIMakerere @radboudumc @UCT_news https://t.co/gX4zhmPdVT
1 month 2 days ago
RT @UNITAID: The @UoLDolphin2 programme investigates the safety and efficacy of dolutegravir in pregnant HIV+ women and their neonates. Find out more about the final 72-week postpartum results in @TheLancet: https://t.co/O9WmgzpDTu https://t.co/p59Zv3dlWC
3 months 5 days ago
We are recruiting a NIHR Academic Clinical Lecturer in Clinical Pharmacology and Therapeutics at University of Liverpool https://t.co/gRrI5C7LQ0
3 months 2 weeks ago
On #WorldAIDSDay we would like to thank all the participants for their time and commitment to the DolPHIN2 trial
3 months 3 weeks ago
RT @AdellineTwimu: Please follow the link below to join the forum through zoom; Dolutegravir in Pregnant HIV Mothers and their Noenates- (DoLPHIn 2) https://t.co/BW8V7GzVIn @IDIMakerere @UoLDolphin2 https://t.co/VNQIRcH5GS
4 months 3 weeks ago
RT @UNITAID: In sub-Saharan Africa, over 1 in 5 HIV-infected pregnant women are diagnosed in late pregnancy each year. @UoLDolphin2 investigates factors that influence late antenatal initiation and the adherence to and retention in combination antiretroviral therapy programmes in pregnancy. https://t.co/gds9CbxJGZ
4 months 4 weeks ago
RT @CatrionaWaitt: @UoLDolphin2 consortium meeting hosted by @livuninews. We've shown that it is possible to do policy - changing research with women in late pregnancy, and have built a strong, international multi disciplinary team. Great final discussion on the next steps. I am excited! @UNITAID https://t.co/LXi6eASMi0
4 months 4 weeks ago

The D2 Consortium

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.

University of Liverpool

Liverpool School of Tropical Medicine

Infectious Diseases Institute

University of Cape Town

Radboud University Medical Centre

Unitaid

Contact us

dolphin [dot] admin [dot] team [at] liverpool [dot] ac [dot] uk

ClinicalTrials.gov Identifier: NCT03249181

Follow us

  • Twitter
A Remora website by Manta Ray Media